You are like those people that believe everything sent via forwarded messages/emails. I'm guessing you are a boomer. Anyone can cut and paste a list of names and try to make the news credible.

Published as an opinion letter is considered factual? Malaysiakini never published erroneous news before? Get your head out of the sand.

BTW, it wasn't an open letter from a bunch of scientists or medical professionals. All fake news starts with placing in "reputable" names, sprinkled here and there to make the news a bit more factual. If you did any research at all, you will see it's always the same names being misused.

It's a boomer issue that boomers can't weed out scams.

Boomer is a term. Not a slur. If you feel slighted, you are definitely a boomer then. Peer reviewed journals? I'm laughing so hard. I tell you what, keep on believing everything you read from whatsapp and FB.

If you had decent critical thinking, you would know where to stand on this issue.

11 is not a lot lol

seriously anyone can cook up journals really

he did say peer reviewed though

not all journals gets pass peer review process.

but where are they?

Thanks, I also agree that Ivermectin is a proven drug for treatment of Covid. We'll wait and see how it progresses. More and more evidence of its effectiveness is showing.

Its still not going to put an end to the pandemic though.

Weh tag la the fella who asked for the links muok

some of u talking like its a silver bullet

plz la

*inject highly specific chemical made by big pharma directly into bloodstream with relatively mild side effects* = tak mau
*ingest broad spectrum chemical (also made by big pharma) with all sorts of potential dosage issue and side effects and liver toxicity* = bring it on
/s

TS ni baca sikit news je dah jadi super expert lulz

TS share punya news dah ada info tu u tak tau baca ke?

aku belajar bahasa malaysia la

I read information on that earlier, seems not viable at this point compared to Ivermectin which is cheap, safe and readily available.



Look at the above post, doctors are giving up on those with less chances of survival citing the lacking of ventilators / ICU beds.

Instead of giving up on them, why not try Ivermectin as a potential treatment? Shall we continue to passively wait for the conclusion of KKM clinical trial with no target end date while citizens continue to die everyday?

Is our sole focus on lock down and vaccination, forgetting about TREATMENT of the sickness?

This is organized by Selangor state government.

Ministry of Health Malaysia starts Ivermectin trial for high risk COVID-19 patients (I-TECH Study)
By DG of Health on June 5, 2021

Effective pharmacologic treatments for COVID-19 remains a challenge. The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial showed dexamethasone, a steroid, improved mortality outcomes for COVID-19 patients in severe stage of disease when oxygen supplementation or mechanical ventilation is required. But for the management of mild and moderate cases, there is lack of treatment, either to prevent disease progression or cut viral transmission.

The COVID-19 clinical characterisation study by MOH specialists and researchers found that for cases admitted to hospitals, 95% had mild illness but about 3.5% subsequently progressed to severe disease. They were mostly of older age (≥51 years) or had underlying co-morbidities such as chronic kidney disease and chronic pulmonary disease that increased their risk for severe disease. However, for high-risk COVID-19 patients, many repurposed antiviral therapies were found ineffective. The World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments (SOLIDARITY) which included Malaysia, found insufficient evidence for the use of remdesivir, hydroxychloroquine, interferon, lopinavir in terms of mortality outcomes. Currently, the Malaysian Consensus Management Guidelines for COVID-19 maintains Favipiravir, as the only antiviral therapy for the management of COVID-19 cases. Even this recommendation may change as more evidence becomes available.

Ivermectin is an FDA-approved anti-parasitic drug widely used for treating several neglected tropical diseases, including onchocerciasis, strongyloidiasis and helminthiases. The “off-label” use of Ivermectin gained global attention due to some promising results by case studies and clinical trials. Yet, the evidence is inconclusive to recommend routine use of Ivermectin for COVID-19. The FDA has not approved Ivermectin for use in treating or preventing Covid-19 in humans, and the WHO only recommends the use of Ivermectin in the setting of clinical trials, in which patients are monitored closely by experienced clinicians and researchers for safety and efficacy. There is an on-going need for adequately powered, well-designed, and well-conducted clinical trials for evidence-based guidance on the role of Ivermectin in the treatment of COVID-19.

Under the circumstances, the Ministry of Health Malaysia and the Institute for Clinical Research (ICR) have initiated a multicentre open-label randomized controlled trial. The Ivermectin Treatment Efficacy in Covid-19 High Risk Patients (I-TECH Study) headed by Infectious Disease (ID) Physician at Hospital Raja Permaisuri Bainun, Ipoh and a team of specialists and Clinical Research Centres (CRC) at 12 MOH hospitals. The trial was approved by Medical Research and Ethics Committee (MREC), MOH on 25 May 2021. The study compares Ivermectin treatment (specific dose with specific duration) with the standard of care alone. The study will enrol 500 subjects from high risk groups aged 50 years and above admitted to MOH hospitals with mild/moderate COVID-19 symptoms (Stage 2-3). The study aims to determine the efficacy of Ivermectin in preventing the progression of COVID-19 to severe disease (Stage 4-5) and in terms of mortality outcomes. ICR has setup a Data Monitoring Board (DMB) consisting of independent ID physicians, clinical trial pharmacists and methodological experts to safeguard the trial patients on the safety and efficacy of the investigation product set by the National Pharmaceutical Regulatory Agency (NPRA).

The First-Patient-In (FPI) was on 31 May 2021, and to date 8 patients have been enrolled. The study is expected to be completed by September 2021.

Thank you.

Tan Sri Dato’ Seri Dr. Noor Hisham bin Abdullah

Director General Ministry of Health Malaysia

5 June 2021

https://kpkesihatan.com/2021/06/05/ministry...s-i-tech-study/

tonight, somebody - or a group of somebodies - is actively bringing inactive /kopitiam threads back to the top

I listened to the live stream and thought it will be taken down by Youtube shortly after.
Surprisingly it is still there.